Search | Clinical Trials Finder

Conditions: Lupus Nephritis
Interventions: Atacicept, Mycophenolate mofetil, Placebo, Corticosteroids; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 16 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: New Orleans, Louisiana • Shreveport, Louisiana • Detroit, Michigan + 9 more

Conditions: Parkinson's Disease
Interventions: Oxaloacetate (OAA), Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Parkinson Disease
Interventions: K0706, Placebo; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Long Beach, California • Panorama City, California • DeLand, Florida + 2 more

Conditions: Peripheral Neuropathy, Neuropathic Pain
Interventions: ADL5859, Duloxetine, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 27
States / cities: Riverside, California • Torrance, California • Kissimmee, Florida + 21 more

Conditions: Schizophrenia
Interventions: Placebo, bitopertin [RO4917838]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 21
States / cities: Carson, California • Oceanside, California • San Diego, California + 17 more

Conditions: Weight Regain Post Bariatric Surgery
Interventions: Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Lung Cancer, Non-Small Cell
Interventions: Dostarlimab, Belrestotug, Pembrolizumab, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Ocala, Florida • Honolulu, Hawaii • Lexington, Kentucky + 4 more

Conditions: Primary Hypercholesterolemia
Interventions: HS-25, Placebo; Drug
Lead sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 27
States / cities: Chandler, Arizona • Phoenix, Arizona • West Hills, California + 24 more

Conditions: Coronary Artery Bypass Surgery, Cognitive Impairment
Interventions: Angiotensin-(1-7), Placebo for Angiotensin-(1-7); Drug
Lead sponsor: University of Arizona; Other
Eligibility: 60 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • Tucson, Arizona • Bethesda, Maryland + 1 more

Conditions: Hepatitis C, Chronic
Interventions: BI201335, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 6
States / cities: San Francisco, California • Baltimore, Maryland • New York, New York + 1 more

Conditions: Post Menopausal Osteoporosis
Interventions: Abaloparatide Transdermal (50 mcg), Abaloparatide Transdermal (100 mcg), Abaloparatide Transdermal (150 mcg), Abaloparatide Injection (80 mcg), Abaloparatide Placebo; Drug
Lead sponsor: Radius Health, Inc.; Industry
Eligibility: Up to 85 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Lakewood, Colorado • Atlanta, Georgia • Bethesda, Maryland

Conditions: Overactive Bladder Syndrome
Interventions: Vaginal estrogen, Mirabegron 50 MG [Myrbetriq]; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: MEDI-559, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 1 Month to 23 Months
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 75
States / cities: Greenville, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more

Conditions: Osteoarthritis, Knee, Pain, Knee
Interventions: Resiniferatoxin, Saline; Drug
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more

Conditions: Hepatocellular Carcinoma
Interventions: ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol), Placebo, Best Supportive Care; Drug · Other
Lead sponsor: Polaris Group; Industry
Eligibility: 18 Years and older
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 21
States / cities: Birmingham, Alabama • Coronado, California • La Jolla, California + 16 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: ABBV-154, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 101
States / cities: Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more

Conditions: Pain
Interventions: [S,S]-Reboxetine; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 61
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 51 more

Conditions: Periodontal Disease
Interventions: ST266, Saline (0.9% NaCl); Biological · Drug
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more

Conditions: Healthy
Interventions: BIIB061, Placebo, 14C-BIIB061; Drug
Lead sponsor: Biogen; Industry
Eligibility: 20 Years to 55 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Evansville, Indiana • Madison, Wisconsin

Conditions: Hyperparathyroidism, Primary, Hypercalcemia
Interventions: Cinacalcet, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 22
States / cities: Lake Forest, California • Lancaster, California • Los Gatos, California + 19 more

Conditions: Abortion, Induced, Abortion, Second Trimester
Interventions: Addition of mifepristone 200 mg 24 hours before induction; Drug
Lead sponsor: Boston University; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Neoplasms, Breast Neoplasms, Breast Cancer
Interventions: AZD8931, anastrozole, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 482 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Chemotherapy-induced Neutropenia
Interventions: EC-18, Placebo; Drug
Lead sponsor: Enzychem Lifesciences Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder, Autism
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Christopher John McDougle, M.D.; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Lexington, Massachusetts

Search by objective public record fields.

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

A Pilot Study of Oxaloacetate in Subjects With Treated PD

Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease

Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety of MEDI-559 in Healthy 1 to <24 Month-Old Children

Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis

Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

A Trial Assessing The Effectiveness and Safety of [S,S]-Reboxetine in Patients With Fibromyalgia

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy

Mifepristone and Mid-Trimester Termination of Pregnancy

Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer

A Safety and PK Study of EC-18 in Healthy Subjects

Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder